Shanghai-based HeartCare Biotech’s silicone rubber artificial blood vessel received FDA Breakthrough Device designation. Its silicone oil-modified surface enhances antithrombogenic properties by 40%. The nano-porous structure permits cellular integration, preventing calcification seen in PTFE alternatives. Clinical trials show 92% 5-year patency rate.
The technology extends to IV catheters and respiratory masks. Global medical silicone rubber market reached $8.5 billion in 2023, with China’s domestic supply rate jumping from 15% to 38%. Under volume-based procurement policies, domestic premium silicone devices cost 40% less than imports. Products-IOTA